Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week phase 3 placebo-controlled study of relamorelin in diabetic gastroparesis
MOH_2019-07-10_004889Phase 3Not yet recruiting
- Sponsor
- Allergan
- Start
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic gastroparesis comparing Relamorelin 10 mcg with Placebo (2 arms). Planned start Dec 2018; status: not yet recruiting.
02
Drugs
relamorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on MOH_2019-07-10_004889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-10_004889.